US Biopharma IPOs Surge, Data For 2018 So Far
Executive Summary
US initial public offerings by biopharmaceutical firms surged in the first 10 months of 2018, even as stock values fell in October. Market dynamics are moving swiftly, and with Moderna Therapeutics looking to raise $600m in an upcoming IPO, the biggest in biotech’s history, the appetite for financing innovation continues to grow despite declining returns.
You may also be interested in...
IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year
Nearly two-thirds of the 67 drug developers that launched an IPO in 2018 were trading below their offering price at the end of the year, bringing the average return to -7.5%. Even so, biopharma companies continue to line up for a US stock market debut.
Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.